Last updated on September 2018

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Brief description of study

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC).

The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. Assessment of a variety of correlative analysis, including evaluation of the effect of palbociclib in genomically defined tumor subgroups, is planned.

Clinical Study Identifier: NCT02513394

Contact Investigators or Research Sites near you

Start Over

Edward Habermehl

Englewood Hospital and Medical Center
Englewood, NJ United States
  Connect »

Edward Habermehl

Hackensack Medical Center
Hackensack, NJ United States
  Connect »

Edward Habermehl

Montefiore Medical Center
Bronx, NY United States
  Connect »

Edward Habermehl

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »